iCellate joins METRO study with aim of analyzing circulating tumor cells (CTCs) in prostate cancer
Stockholm, Sweden – March 21, 2023 – iCellate joins as new study partner in the METRO study and will use its liquid biopsy technology for biomarker analyses in oligometastatic prostate cancer patients. The METRO consortium is comprised of eight Swedish hospitals including university hospitals (all but Linköping and Uppsala), Ryhov Hospital, Södersjukhuset, and Sankt Göran in Stockholm. Karin Söderkvist of Umeå University Hospital is the lead Principal Investigator.The study will recruit patients with oligometastatic prostate cancer. Standard of care therapy (SOC) will be compared with SOC